Acotec Scientific Holdings Limited (6669.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.

Industry: Medical - Devices
Sector: Healthcare
Headquarters: CN
CEO: Jing Li
Listed since: Aug 24, 2021
Employees: 653

Market position

Day range

Current HK$6.395

HK$6.36HK$6.515

52-week range

Current HK$6.395

HK$5.99HK$15.47

Open: HK$6.405
Previous close: HK$6.465
Volume: 206K; 0.55× average
Average volume: 373.4K; Average daily volume
Market cap: 1.91B HKD
Beta: -0.03; Market reference 1
50-day average: HK$7.7961; -17.97% below average
200-day average: HK$11.0724; -42.24% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 3.55B CNY
P/E (TTM): 13.66×
P/B (TTM): 1.13×
P/S (TTM): 2.54×
EV / EBITDA: 27.38×
Earnings yield: 3.22%
Free cash flow yield: 3.93%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 73.89%
Operating margin: 20.66%
Net margin: 18.49%
Return on equity: 8.07%
Return on assets: 6.38%
Return on invested capital: 7.51%

Financial health

Debt / equity: 0.17×
Current ratio: 5.73×
Altman Z-score: 3.6
Piotroski F-score: 5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

644.63M CNY+20.72%

Operating income

133.15M CNY+108.02%

Net income

119.18M CNY+127.97%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	644.63M CNY	533.99M CNY	473.85M CNY	395.55M CNY	303.81M CNY
Cost of goods sold	168.32M CNY	131.27M CNY	96.43M CNY	59.19M CNY	37.87M CNY
Gross profit	476.31M CNY	402.72M CNY	377.42M CNY	336.35M CNY	265.94M CNY
Research and development	213.67M CNY	216.77M CNY	190.07M CNY	183.8M CNY	141.29M CNY
Selling, general, and administrative	182.33M CNY	157.59M CNY	181.32M CNY	160.51M CNY	158.02M CNY
Operating expenses	343.16M CNY	338.72M CNY	352.41M CNY	264.28M CNY	202.52M CNY
Interest income	25.67M CNY	30.15M CNY	18.51M CNY	20.26M CNY	4.73M CNY
Interest expense	9.39M CNY	11.5M CNY	9.83M CNY	1.42M CNY	3.82M CNY
Depreciation and amortization	23.84M CNY	49.98M CNY	46.26M CNY	19.44M CNY	12.4M CNY
Operating income	133.15M CNY	64.01M CNY	25.01M CNY	72.08M CNY	63.42M CNY
Net income	119.18M CNY	52.28M CNY	14.49M CNY	70.14M CNY	−79.08M CNY